STOCK TITAN
  1. Home
  2. News
  3. CTSO

Cytosorbents Corp. - CTSO STOCK NEWS

Welcome to our dedicated page for Cytosorbents news (Ticker: CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents stock.

CytoSorbents Corporation (NASDAQ: CTSO) is a prominent player in the field of critical care immunotherapy, with a strong focus on blood purification technologies. The company has made significant strides with its flagship product, CytoSorb®, which has received approval in the European Union and is distributed across 40 countries globally. CytoSorb® is an extracorporeal cytokine adsorber designed to mitigate the 'cytokine storm' or 'cytokine release syndrome' that can lead to severe inflammation, organ failure, and death in critical conditions such as sepsis, burn injuries, trauma, lung injuries, and pancreatitis. It is also employed in cancer immunotherapy and during cardiac surgeries to remove inflammatory mediators that may cause post-operative complications.

The core technology of CytoSorbents is based on biocompatible, highly porous polymer beads that efficiently purify the blood. Apart from CytoSorb®, the company offers other innovative products like ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR, which cater to different aspects of critical care and blood purification.

CytoSorbents operates through various segments, including Direct Sales, Distributors/Strategic Partners, and Government contracts. Its revenue is primarily driven by product sales, particularly in Germany, with additional income sourced from grants by agencies in the United States.

In Q3 2023, CytoSorbents reported a 20% growth in product sales, reaching $7.8 million, compared to $6.5 million in Q3 2022. The total revenue for the same quarter was approximately $8.8 million. The company is also advancing its pivotal STAR-T trial, with the database lock nearing completion and initial data analysis expected before the year's end.

For more detailed financial results and updates, investors can refer to the company’s official filings, such as the Form 10-K for the period ending December 31, 2023, and the Form 10-Q for the period ending March 31, 2024, available on the SEC website.

News

CytoSorbents to Report Fiscal 2023 Operating and Financial Results

Rhea-AI Summary
CytoSorbents Corporation (CTSO) will report fiscal 2023 financial results on March 14th, 2024. The live conference call will discuss operational and financial progress during Q4 2023 and fiscal year ending December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
conferences earnings
-
News

CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) CEO, Dr. Phillip Chan, to present at TD Cowen 44th Annual Health Care Conference in Boston. The company will also hold in-person meetings with investors during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) reports statistically significant reductions in multiple organ failure and dysfunction in heart transplant patients using CytoSorb® blood purification. The groundbreaking randomized controlled trial (RCT) published in the European Society of Cardiology journal, ESC Heart Failure, showed that patients who received CytoSorb had better hemodynamic stability, lower rates of post-operative shock, shorter time on mechanical ventilation, lower rates of acute kidney injury, and shorter time in the ICU. The study also revealed similar rates of cardiac allograft rejection, 30-day mortality, and 1-year survival between the CytoSorb group and the control group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) announces an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board analysis for the pivotal U.S. and Canadian STAR-T trial. The study did not meet the primary effectiveness endpoint in the overall patient population undergoing different types of cardiac surgeries, but demonstrated evidence of reduced bleeding complications in patients undergoing isolated coronary artery bypass graft surgery. The safety and effectiveness data may support the regulatory submission of DrugSorb-ATR to the U.S. FDA and Health Canada. The full results of the STAR-T trial are expected to be presented at the American College of Cardiology 2024 conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.44%
Tags
none
-
News

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering

Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) announces the closing of a registered direct offering, raising approximately $9.83 million in net proceeds. The offering included the sale of 7,733,090 shares of registered common stock and warrants to purchase up to 2,706,561 shares of common stock. The company's executive officers, directors, and certain non-executive officer employees also participated in the financing with a combined investment of $435,000. The net proceeds will be used for general corporate purposes, including funding clinical and regulatory efforts, supporting growth initiatives, investing in clinical studies, and funding ongoing R&D initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.53%
Tags
offering
-
News

CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) reported unaudited Q3 2023 financial results, including a 20% increase in product sales to $7.8M, total revenue of $8.8M, and a 72% product gross margin. The pivotal STAR-T trial remains blinded, with initial data analysis completion expected before year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
earnings
News

CytoSorbents to Report Third Quarter 2023 Operating and Financial Results

Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) will report its third quarter 2023 operating and financial results on November 9th, 2023. A live presentation webcast and Q&A session will be held at 4:30 PM EDT on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.83%
Tags
conferences earnings
-
News

CytoSorbents to Present at the 8th Annual Dawson James Conference

Rhea-AI Summary
CytoSorbents Corporation CEO to present at Dawson James Small Cap Growth conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
conferences
-
News

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

Rhea-AI Summary
CytoSorbents Corporation announces upcoming presentations at the 37th European Association of Cardio-Thoracic Surgery (EACTS) Annual Meeting, including second analysis from the International STAR Registry. First analysis shows favorable results compared to a previous study. Second analysis includes broader range of heart surgeries and data on patients treated with CytoSorb to reduce seven different antithrombotic medications. Overall, the use of intraoperative antithrombotic drug removal is associated with lower incidence of serious bleeding. No serious device-related adverse events were observed. Other studies highlight successful use of CytoSorb in prophylactic removal of antithrombotic drugs during off-pump CABG surgery. CytoSorbents will also host a satellite research symposium. Positive outlook for CytoSorb's ability to reduce perioperative bleeding risk.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
conferences
News

CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer

Rhea-AI Summary
CytoSorbents Corporation re-appoints Kathleen P. Bloch as full-time CFO, effective retroactively to September 2, 2023. Bloch's return provides continuity and stability to the company as it targets US and Canadian approval for DrugSorb®-ATR and capitalizes on improvements in the acute care markets and investments in CytoSorb® business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
none

FAQ

What is the current stock price of Cytosorbents (CTSO)?

The current stock price of Cytosorbents (CTSO) is $0.9366 as of January 3, 2025.

What is the market cap of Cytosorbents (CTSO)?

The market cap of Cytosorbents (CTSO) is approximately 45.8M.

What is CytoSorbents Corporation's primary focus?

CytoSorbents focuses on critical care immunotherapy and blood purification technologies, particularly for treating life-threatening conditions.

What is CytoSorb®?

CytoSorb® is an extracorporeal cytokine adsorber used to reduce severe inflammation and prevent organ failure in critical illnesses.

In which regions is CytoSorb® approved?

CytoSorb® is approved in the European Union and distributed in 40 countries worldwide.

What was CytoSorbents' product sales growth in Q3 2023?

Product sales grew 20% to $7.8 million in Q3 2023 compared to $6.5 million in Q3 2022.

What are some other products offered by CytoSorbents?

In addition to CytoSorb®, CytoSorbents offers products like ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Where does CytoSorbents generate most of its revenue?

Most revenue comes from product sales in Germany, with additional income from U.S. government grants.

What are the main segments through which CytoSorbents operates?

CytoSorbents operates through Direct Sales, Distributors/Strategic Partners, and Government segments.

What are the latest developments in CytoSorbents’ STAR-T trial?

The STAR-T trial remains blinded, with a database lock nearing and initial data analysis expected before the end of the year.

Where can investors find detailed financial results for CytoSorbents?

Detailed financial results can be found in the company's Form 10-K and Form 10-Q filings available on the SEC website.

Who should be contacted for investor relations at CytoSorbents?

For investor relations, contact Eric Ribner at LifeSci Advisors, LLC.
Stock CTSO logo
Cytosorbents Corp.

Nasdaq:CTSO

CTSO Rankings

#4969 Ranked by Market Cap
N/A Ranked by Dividends

CTSO Stock Data

45.83M
52.69M
3.9%
33.29%
2.56%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
PRINCETON